Bausch + Lomb Corporation (BLCO) Stock Analysis
Falling Knife setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $15.29 — A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care (57.0%).
Bausch + Lomb is a fully integrated eye health company with ~$5.1B in 2025 revenues across Vision Care (57%), Pharmaceuticals (25%), and Surgical (18%) segments, sold in ~100 countries with ~13,000 employees and ~400 products. It is 88%-owned by Bausch Health Companies (BHC),... Read more
Sell if holding. Analyst target reached at $15.29 — A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care (57.0%). Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Score 5.5/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 48d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-11Recent Developments — Bausch + Lomb Corporation
Latest news
- NEWS Bausch + Lomb Corporation 2026 Q1 - Results - Earnings Call Presentation (NYSE:BLCO) 2026-04-29 - Seeking Alpha — Seeking Alpha neutral
- NEWS Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - StockStory — StockStory positive
- NEWS Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - TradingView — TradingView positive
- NEWS Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally? - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVision Care57%10-K Item 1: 'Vision Care | | $ | 2,923 | | | 57 | % | | $ | 2,739 | | | 57 | %'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $15.29 — A.R:R 0.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care (57.0%). Chart setup: Death cross, below all MAs, RSI 36, MACD bearish. Prior stop was $14.49. Score 5.5/10, moderate confidence.
Take-profit target: $15.55 (+1.7% upside). Prior stop was $14.49. Stop-loss: $14.49.
Concentration risk — Product: Vision Care (57.0%); Analyst target reached - limited upside remaining; Consecutive earnings misses (2).
Bausch + Lomb Corporation trades at a P/E of N/A (forward 14.2). TrendMatrix value score: 7.3/10. Verdict: Sell.
18 analysts cover BLCO with a consensus score of 3.6/5. Average price target: $18.
What does Bausch + Lomb Corporation do?Bausch + Lomb is a fully integrated eye health company with ~$5.1B in 2025 revenues across Vision Care (57%),...
Bausch + Lomb is a fully integrated eye health company with ~$5.1B in 2025 revenues across Vision Care (57%), Pharmaceuticals (25%), and Surgical (18%) segments, sold in ~100 countries with ~13,000 employees and ~400 products. It is 88%-owned by Bausch Health Companies (BHC), which controls the business direction; a separation from BHC is being evaluated.